Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.
Daniel Morgensztern, MD, professor, medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine; medical oncologist, Siteman Cancer Center, discusses ongoing research with amivantamab-vmjw (Rybrevant) in non–small cell lung cancer (NSCLC).
Amivantamab, a bispecific antibody that targets EGFR and MET, was approved by the FDA in May 2021 for patients with EGFR exon 20 insertions, Morgensztern says. This approval has also led to the initiation of the phase 3 PAPILLON study (NCT04538664), which is looking at chemotherapy with or without amivantamab in patients with EGFR exon 20 insertions, Morgensztern explains.
In patients with EGFR mutations, amivantamab is also being combined with lazertinib (Leclaza), a third-generation TKI, Morgensztern notes. Encouraging frontline data in this population includes findings from the phase 1 CHRYSALIS trial (NCT02609776). Now, the combination is under study in the phase 3 MARIPOSA trial (NCT04487080), which is looking at first-line amivantamab plus lazertinib vs single-agent lazertinib and osimertinib (Tagrisso) in locally advanced or metastatic NSCLC, Morgensztern concludes.